Efficacy and safety of eltrombopag in combination with dexamethasone as first‐line treatment in adult patients with newly diagnosed immune thrombocytopenia

Left panel: Scheme of the XPAG-ITP trial. The dexamethasone monotherapy (DEX) arm consisted of DEX 40 mg/day for days 1-4 for one to three cycles every 28 days to a maximum of 12 weeks, cycles 2 + 3 were optional. Patients randomised to eltrombopag combined with dexamethasone (ETB + DEX) received eltrombopag (ETB) in combination with a short course of high-dose DEX beginning on day 1 (40 mg/day during days 1-4). The starting dose of ETB was 50 mg/day for 2 weeks; thereafter, the ETB dose was increased by 25 mg for all patients who did not achieve the target platelet count of ≥50 × 10<sup>9</sup>/L. The ETB tapering was performed by decreasing the dose by 25 mg every 2 weeks to a minimum dose of 25 mg every other day for all patients. Right upper panel: Clinical outcomes in patients treated with first-line ETB + DEX. Patients displayed a qualitatively longer response duration and qualitatively reduced usage of rescue medication. Right lower panel: The immunological T-cell response was different in treatment responders and non-responders. Patients with sustained response (responders) displayed a high T-cell clonality at baseline. Clones are depicted as bubbles (right side).

Authors

Institutions

Publication Details

Journal
British Journal of Haematology
Published
2026-01-06
DOI
https://doi.org/10.1111/bjh.70312
Primary Topic
Platelet Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of eltrombopag in combination with dexamethasone as first‐line treatment in adult patients with newly diagnosed immune thrombocytopenia

Jakob Robert Passweg, Tamara Tesanovic, Thomas Stauch, Claudia Quiering et al.
British Journal of Haematology
Platelet Disorders and Treatments
article

Efficacy and safety of eltrombopag in combination with dexamethasone as first‐line treatment in adult patients with newly diagnosed immune thrombocytopenia

Jakob Robert Passweg, Tamara Tesanovic, Thomas Stauch, Claudia Quiering, Roland Repp, Karolin Trautmann‐Grill, A Matzdorff, J Chromík, Martina Stauch, Christoph Schultheiß, Clemens Schulte, Oliver Meyer, Andreas Holbro, Mathias Hänel, Annaïse Jauch, Mathias Rummel, Olivier Bignucolo, Gerda Silling, Bastian Fleischmann, Mascha Binder, Paul Schmidt‐Barbo, Frank Richter, Sabine Jahn, Falk Nimmerjahn, Manfred Welslau
article en

Abstract

Left panel: Scheme of the XPAG-ITP trial. The dexamethasone monotherapy (DEX) arm consisted of DEX 40 mg/day for days 1-4 for one to three cycles every 28 days to a maximum of 12 weeks, cycles 2 + 3 were optional. Patients randomised to eltrombopag combined with dexamethasone (ETB + DEX) received eltrombopag (ETB) in combination with a short course of high-dose DEX beginning on day 1 (40 mg/day during days 1-4). The starting dose of ETB was 50 mg/day for 2 weeks; thereafter, the ETB dose was increased by 25 mg for all patients who did not achieve the target platelet count of ≥50 × 10<sup>9</sup>/L. The ETB tapering was performed by decreasing the dose by 25 mg every 2 weeks to a minimum dose of 25 mg every other day for all patients. Right upper panel: Clinical outcomes in patients treated with first-line ETB + DEX. Patients displayed a qualitatively longer response duration and qualitatively reduced usage of rescue medication. Right lower panel: The immunological T-cell response was different in treatment responders and non-responders. Patients with sustained response (responders) displayed a high T-cell clonality at baseline. Clones are depicted as bubbles (right side).

British Journal of HaematologyVol. 208(2)
Goethe University Frankfurt (DE), SIB Swiss Institute of Bioinformatics (CH), NHS Blood and Transplant (GB), University of Freiburg (DE), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Justus-Liebig-Universität Gießen (DE), University Hospital of Basel (CH), Novartis (Germany) (DE), Klinikum Aschaffenburg (DE), Eberswalde University for Sustainable Development (DE), Applied Dynamics International (United States) (US), Department of Biomedicine Basel (CH), University Hospital Frankfurt (DE), Jena University Hospital (DE), Klinik Donaustauf (DE), Praxis für Hämatologie und Onkologie (DE), Aschaffenburg University of Applied Sciences (DE), Klinikum Chemnitz (DE), Clinical Research Center Kiel (DE), Technische Universität Dresden (DE), RWTH Aachen University (DE)
Good health and well-being
Openalex Percentile: Top 96%
Platelet Disorders and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.